Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:18 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 6,446 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed No phase listed Observational

The Family Investigation of Nephropathy and Diabetes Study

NCT00301249
View directory record Official record
Conditions
Diabetes, Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
9,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Nov 3, 2026, 4:18 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Apple Cider Vinegar Supplementation on 24-hour Urine Chemistry in Adults

NCT07389226
View directory record Official record
Conditions
Kidney Stones, Urine Specimen Collection
Interventions
Apple Cider Vinegar
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 4:18 PM EST
Completed Phase 1 Interventional

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

NCT01069926
View directory record Official record
Conditions
Glucose Lowering
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Orlando, Florida • Overland Park, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Nov 3, 2026, 4:18 PM EST
Completed Phase 2 Interventional Results available

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

NCT04633889
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 4:18 PM EST
Not listed No phase listed Observational

Genetic Predictors of Renal Dysfunction Following Heart Transplantation

NCT01686191
View directory record Official record
Conditions
Heart Transplantation, Chronic Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 3, 2026, 4:18 PM EST
Completed Not applicable Interventional

Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis

NCT01062984
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD)
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Nov 3, 2026, 4:18 PM EST
Terminated Phase 1 Interventional

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06630247
View directory record Official record
Conditions
Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Interventions
XL495, ADC cytotoxic agents
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Nov 3, 2026, 4:18 PM EST
Completed No phase listed Observational

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Nov 3, 2026, 4:18 PM EST
Withdrawn No phase listed Observational

Presep and Vascath Interaction Study

NCT00739089
View directory record Official record
Conditions
Hemodynamics, Renal Dialysis, Sepsis, Shock
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Nov 3, 2026, 4:18 PM EST
Not listed Not applicable Interventional

Alio WEAR Study: Long-term Wear of the Alio Platform

NCT06056739
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Alio platform
Device
Lead sponsor
Alio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Huntley, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Nov 3, 2026, 4:18 PM EST
Completed Not applicable Interventional

Network Interventions to Reduce Disparities in Living Kidney Donation

NCT05255757
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Script Intervention, Search Intervention
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Nov 3, 2026, 4:18 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

NCT05286801
View directory record Official record
Conditions
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Tiragolumab, X-Ray Imaging
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 3, 2026, 4:18 PM EST
Completed No phase listed Observational

Evaluation of Immunobiogram® as a Tool in Adjustment of Immunosuppressant Therapy for Renal Transplant

NCT03562845
View directory record Official record
Conditions
Kidney Transplantation
Interventions
NA-Observational only
Other
Lead sponsor
Biohope Scientific Solutions for Human Health, S.L.
Industry
Eligibility
25 Years to 69 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Nov 3, 2026, 4:18 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
View directory record Official record
Conditions
Renal Impairment
Interventions
HM15912
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Nov 3, 2026, 4:18 PM EST
Terminated Phase 1 Interventional

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

NCT00689065
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
CALAA-01
Drug
Lead sponsor
Calando Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Nov 3, 2026, 4:18 PM EST
Recruiting Not applicable Interventional

GI Oxalate Absorption

NCT05356000
View directory record Official record
Conditions
Bariatric Surgery Candidate, Kidney Stone
Interventions
Special low-oxalate diet followed by all-day visit to University of Chicago research clinic
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Nov 3, 2026, 4:18 PM EST
Active, not recruiting Not applicable Interventional

Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

NCT04669444
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Cardiac Failure, Extracorporeal Membrane Oxygenation Complication, Respiratory Failure, Renal Failure, Critical Illness, Pulmonary Disease
Interventions
Ventilator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Nov 3, 2026, 4:18 PM EST
Suspended Phase 1 Interventional

Islet Allotransplantation in Type 1 Diabetes

NCT01705899
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Pancreatic Islets
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2033
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 3, 2026, 4:18 PM EST
Completed No phase listed Observational

Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes

NCT01143532
View directory record Official record
Conditions
Kidney Disease, Kidney Transplantation, Kidney Failure, Chronic
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Nov 3, 2026, 4:18 PM EST
Completed Phase 3 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01320202
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Drug · Device
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Bakersfield, California • Chula Vista, California • Cudahy, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Nov 3, 2026, 4:18 PM EST
Not yet recruiting Phase 1 Interventional

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07848295
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
BMS-986527, Nivolumab, Cabozantinib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Basking Ridge, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 3, 2026, 4:18 PM EST
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Nov 3, 2026, 4:18 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Duke APOL1 Research Biorepository

NCT04160507
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Biorepository
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 3, 2026, 4:18 PM EST
Terminated No phase listed Observational Results available

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

NCT03709771
View directory record Official record
Conditions
Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions
Ambulatory Blood Pressure Measurement
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 3, 2026, 4:18 PM EST